StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com

SELLAS Life Sciences Prices $150 Million Stock Offering After Phase 3 Win

SELLAS Life Sciences filed a prospectus supplement for a $150 million underwritten common stock offering, the same day it reported positive topline results from its pivotal Phase 3 REGAL trial in acute myeloid leukemia.

What happened

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) filed a preliminary prospectus supplement on November 17, 2026 for an underwritten public offering of $150 million of common stock, according to the 424B5 filing. The company also granted the underwriters a 30-day option to buy up to an additional $22,500,000 of shares at the public offering price, less discounts and commissions. J.P. Morgan and TD Cowen are joint book-running managers.

The filing does not state a per-share price; the pricing table is left blank in this preliminary version. It cites the November 16, 2026 closing price of $7.47 per share as the last reported Nasdaq price. SELLAS is listed on the Nasdaq Capital Market.

The same filing discloses that on November 17, 2026 the company announced positive topline results from its pivotal randomized Phase 3 REGAL trial of galinpepimut-S (GPS) as maintenance monotherapy in acute myeloid leukemia (AML). SELLAS says it expects the study to serve as the basis for a Biologics License Application to the FDA in the first half of 2027, subject to agreement with the agency. The filing does not say the offering proceeds are tied to the trial result beyond describing the offering and the results in the same document.

The company and the trial

SELLAS describes itself in the filing as a late-stage clinical biopharmaceutical company developing cancer therapeutics. Its lead candidate, GPS, is a peptide immunotherapy licensed from Memorial Sloan Kettering Cancer Center that targets the WT1 protein, which the company says is present in 20 or more cancer types. Its second candidate, SLS009 (tambiciclib), is a small molecule CDK9 inhibitor licensed from GenFleet Therapeutics for all uses worldwide except Greater China.

The REGAL trial enrolled 126 patients at about 95 sites in North America, Europe and Asia. Patients were randomized to GPS or best available treatment; the primary endpoint is overall survival. The filing says the pre-specified threshold of 80 deaths, which triggers the final analysis, was reached on October 28, 2026. The filing does not quantify the topline results — no hazard ratio, p-value or survival figures appear in the excerpt provided.

SELLAS reports no revenue; its most recent annual revenue was zero for the period ending December 31, 2023. The filing notes the company is a "smaller reporting company" but expects to no longer qualify after the current calendar year.

The stock move

The stock closed at $19.15 on the event date, up 156.36% from the prior close of $7.47, on volume of 119,486,326 shares — about 17.5 times its average volume of 6,822,945, according to the price data. The sources do not state what drove the move; the filing, dated the same day, discloses the positive REGAL topline announcement, but the provided materials do not establish a causal link between that announcement and the price change.

What this means

A 424B5 is the prospectus supplement a company files when it actually sells securities off an already-effective shelf registration. The shelf itself is the earlier Form S-3, filed March 20, 2026, which this filing describes as an "automatic shelf" for a "well-known seasoned issuer." That status lets a company register securities in advance and then pull them off the shelf when it wants to raise money, rather than filing a full registration statement each time.

This is an underwritten offering of common stock — the company's basic equity — not bonds or convertible notes. In an underwritten deal, banks buy the shares from the issuer and resell them to investors; the underwriting discount is their compensation, and "proceeds to SELLAS before expenses" is what the company keeps. The blank pricing grid is normal for a preliminary supplement: the final per-share price and total proceeds are set when the deal prices, which the filing says is expected on or about a date left open in this version.

The 30-day option for up to $22,500,000 of additional shares is a standard "greenshoe," which lets underwriters cover excess demand or stabilize the aftermarket. The key consequence for existing holders is dilution: the supplement contains a "Dilution" section, and new shares sold increase the share count, reducing each existing share's claim on earnings. The filing does not state how many shares will be outstanding after the offering.

What happens next, per the filing's own terms, is that the offering prices and shares are delivered on or about the closing date. Whether SELLAS files the BLA in the first half of 2027 is a stated expectation subject to FDA agreement, not a completed event.

Sources

Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.